Coeptis Therapeutics Enhances AI Capabilities with New Platform
Coeptis Therapeutics Enhances AI Capabilities
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) proudly announces the successful integration of the NexGenAI Affiliates Network platform, alongside the inception of Coeptis Technologies. This strategic acquisition marks a significant step towards enhancing the company’s growth and expanding its reach within the biopharmaceutical landscape.
The NexGenAI Affiliates Network platform, engineered by NexGenAI Solutions Group, Inc., presents cutting-edge AI-driven marketing software integrated with advanced robotic process automation (RPA). This ingenious platform offers profound benefits enabling marketers to process large datasets, refine their campaigns, enhance customer interactions, and optimize company operations. Such capabilities are pivotal for businesses working within the tightly regulated realms of biotech and pharmaceuticals.
Dave Mehalick, the President and CEO of Coeptis Therapeutics, expressed enthusiasm about the acquisition, stating, "Integrating the NexGenAI Affiliates Network platform represents an essential upgrade to our services. In the competitive and often regulatory-heavy domains of biotech and pharma, centralized tools that promote effective marketing, streamline business operations, and yield measurable results are indispensable."
According to Anshuman Dash, who played a crucial role in the development of the platform, this collaboration signifies a transformative advancement. He remarked, "By melding NexGenAI’s innovative solutions with Coeptis’ vision, we are poised to redefine the operational frameworks of marketing strategies—serving both the partners we collaborate with and the industries we impact."
This acquisition underscores Coeptis' commitment to harnessing the power of advanced technologies in pursuit of progress within the biopharmaceutical field. As they integrate AI-driven marketing solutions, Coeptis aims to arm businesses with tools that will help them navigate the complexities of marketing in highly competitive sectors.
Mehalick further elaborated, stating that the essential role of advanced tools in the competitive landscape is not merely advantageous but essential. With the challenges faced by biotech, pharma, and multi-level marketing (MLM) industries, Coeptis acknowledges the necessity for innovation.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. and its subsidiaries, including Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc., focus on pioneering cell therapy platforms capable of transforming traditional treatment methods for cancer, autoimmune disorders, and infectious diseases. Their innovative product portfolio includes licensed assets from Deverra Therapeutics, highlighting technologies in the clinical stages, such as DVX201, which utilizes unmodified natural killer cells.
In addition, Coeptis is making strides with their universal, multi-antigen CAR technology developed through collaborations with esteemed institutions, such as the University of Pittsburgh and the Karolinska Institute.
About NexGenAI
NexGenAI Holding Group Inc., along with its subsidiary NexGenAI Solutions Group, Inc., has developed an advanced suite of tools aimed at optimizing marketing strategies through AI and RPA capabilities. Their innovative platform revolutionizes business operations across diverse sectors by enabling companies to achieve increased efficiency and robust growth through automation and optimization.
Frequently Asked Questions
What is the NexGenAI Affiliates Network platform?
The NexGenAI Affiliates Network platform is an advanced AI-driven marketing tool designed to enhance operations and marketing strategies in various industries.
How will Coeptis benefit from this acquisition?
The acquisition allows Coeptis to integrate innovative marketing solutions that will improve operational efficiencies and enhance company growth in regulated industries.
What is Coeptis Therapeutics' primary focus?
Coeptis Therapeutics specializes in developing innovative cell therapy platforms targeting cancer, autoimmune diseases, and infectious diseases.
Who is leading Coeptis Therapeutics?
Dave Mehalick serves as the President and CEO of Coeptis Therapeutics.
What technologies are included in Coeptis' product portfolio?
Coeptis' product portfolio features advanced technologies, including cellular immunotherapy and CAR technologies developed in collaboration with notable research institutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.